Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) had its price target reduced by stock analysts at Oppenheimer from $16.00 to $13.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Oppenheimer's target price would suggest a potential upside of 75.20% from the stock's previous close.
A number of other analysts have also weighed in on the stock. Lake Street Capital lowered their price target on shares of Bioceres Crop Solutions from $25.00 to $13.00 and set a "buy" rating for the company in a report on Wednesday, September 11th. Canaccord Genuity Group decreased their price target on Bioceres Crop Solutions from $12.50 to $10.00 and set a "buy" rating on the stock in a report on Thursday. Roth Mkm lowered their price objective on Bioceres Crop Solutions from $15.00 to $13.00 and set a "buy" rating for the company in a research report on Wednesday, September 11th. Canaccord Genuity Group upgraded shares of Bioceres Crop Solutions to a "strong-buy" rating in a research report on Friday, July 19th. Finally, Roth Capital upgraded shares of Bioceres Crop Solutions to a "strong-buy" rating in a research report on Tuesday, July 2nd. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $12.25.
Check Out Our Latest Stock Analysis on Bioceres Crop Solutions
Bioceres Crop Solutions Price Performance
BIOX traded down $0.13 during trading on Monday, hitting $7.42. The company's stock had a trading volume of 294,810 shares, compared to its average volume of 80,152. The company has a quick ratio of 0.91, a current ratio of 1.28 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $465.95 million, a price-to-earnings ratio of 747.00 and a beta of 0.47. The firm's 50 day moving average price is $8.92 and its two-hundred day moving average price is $10.51. Bioceres Crop Solutions has a 12 month low of $7.15 and a 12 month high of $14.05.
Bioceres Crop Solutions (NASDAQ:BIOX - Get Free Report) last released its quarterly earnings results on Monday, September 9th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.20 by ($0.23). Bioceres Crop Solutions had a net margin of 0.68% and a return on equity of 0.93%. The business had revenue of $124.30 million during the quarter, compared to the consensus estimate of $126.75 million. During the same period in the prior year, the firm earned ($0.06) earnings per share. Sell-side analysts forecast that Bioceres Crop Solutions will post 0.39 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bioceres Crop Solutions
Several institutional investors have recently modified their holdings of BIOX. Oppenheimer & Co. Inc. bought a new position in Bioceres Crop Solutions during the 1st quarter worth approximately $139,000. Lazard Asset Management LLC acquired a new position in shares of Bioceres Crop Solutions in the 1st quarter valued at $212,000. Ping Capital Management Inc. acquired a new position in shares of Bioceres Crop Solutions in the 2nd quarter valued at $448,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Bioceres Crop Solutions in the 2nd quarter valued at $472,000. Finally, Dimensional Fund Advisors LP raised its stake in Bioceres Crop Solutions by 9.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 61,330 shares of the company's stock worth $688,000 after buying an additional 5,341 shares during the period. 17.68% of the stock is currently owned by institutional investors and hedge funds.
About Bioceres Crop Solutions
(
Get Free Report)
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops.
Further Reading
Before you consider Bioceres Crop Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioceres Crop Solutions wasn't on the list.
While Bioceres Crop Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
